A randomized double-blind parallel-group multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 1

Go Back to All Clinical Trials

A randomized double-blind parallel-group multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 1

Brief description of study

People with ankylosing spondylitis (AS) have reduced movement of the spine as well as significant pain in the lower back, buttocks, and often in other joints in the body. The purpose of the study is to determine the safety and benefit of taking secukinumab 300mg, compared to 150mg, in patients with active ankylosing spondylitis. This study will also look to see if treatment with secukinumab has an impact on daily activity (i.e. movement) and quality of sleep.

Clinical Study Identifier: s18-01066

ClinicalTrials.gov Identifier: NCT03350815

Clinical Research Studies

A randomized double-blind parallel-group multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 1

Brief description of study

Recruitment Status

212-263-4432

646-754-7432